PP
ACRS icon

Paloma Partners’s Aclaris Therapeutics ACRS Stock Holding History

Paloma Partners’s Portfolio ACRS Stock Details ACRS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q3 		– Sell
-79,200
Closed -$87.1K – 1109
2024
Q2 		$87.1K Buy
+79,200
New +$93.1K ﹤0.01% 1090
2020
Q3 		– Sell
-71,800
Closed -$116K – 2020
2020
Q2 		$116K Buy
+71,800
New +$96.2K ﹤0.01% 1867
2020
Q1 		– Sell
-14,650
Closed -$28K – 1180
2019
Q4 		$28K Buy
+14,650
New +$24.3K ﹤0.01% 2093
2019
Q3 		– Sell
-20,500
Closed -$45K – 1904
2019
Q2 		$45K Sell
20,500
-400
-2% -$2.18K ﹤0.01% 1659
2019
Q1 		$125K Buy
+20,900
New +$139K ﹤0.01% 1575

Other funds holding ACRS

BCM
BML Capital Management Zionsville, Indiana $156M AUM 129.82% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
D.E. Shaw & Co
D.E. Shaw & Co New York $166B AUM 43.98% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
RSCM
Rock Springs Capital Management Baltimore, Maryland $1.7B AUM 93.03% 1-Year Est. Return
SCM
Stonepine Capital Management Bend, Oregon $250M AUM 77.6% 1-Year Est. Return
Acadian Asset Management
Acadian Asset Management Boston, Massachusetts $70.5B AUM 36% 1-Year Est. Return
TC
Trium Capital London, United Kingdom $163M AUM 45.8% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

Paloma Partners's ACRS Position: Q3 2024 in Review

Paloma Partners sold out of Aclaris Therapeutics (ACRS) in Q3 2024, closing a stake of 79,200 shares — an estimated $87.1K sold.

Paloma Partners first reported a position in ACRS in Q1 2019 and held it in 5 quarters. The position peaked at $125K in Q1 2019. 81 funds tracked by Wall St. Rank hold ACRS as of Q3 2024.

  • Paloma Partners reported no remaining Aclaris Therapeutics position as of Q3 2024 after selling out during the quarter.
  • Paloma Partners sold 79,200 Aclaris Therapeutics shares in Q3 2024, an estimated $87.1K.
  • Paloma Partners first reported a position in Aclaris Therapeutics in Q1 2019 and held it in 5 quarters.
  • Paloma Partners's Aclaris Therapeutics position peaked at $125K in Q1 2019.
  • 81 funds tracked by Wall St. Rank held Aclaris Therapeutics as of Q3 2024.

Based on Paloma Partners's 13F filing for Q3 2024, filed 14 Nov 2024.